clinical trial · NCT07007962
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
Immune Thrombocytopeniarilzabrutinib
brief summary
This is a multinational, open label, single arm study that will evaluate the impact of early multi-immune modulation with rilzabrutinib in adult ITP patients who failed first-line treatment. The study includes a screening period (up to 8 weeks), a primary analysis period (up to 28 weeks), a long-term extension period for selected participants (28 weeks) and a 24-week follow-up period only for eligible participants.
started
Oct 24, 2025
primary completion
Nov 5, 2027
completion
Dec 30, 2028
last updated
Apr 3, 2026
official title
A Multi-center, Open-label, Single-arm Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol